Why this trial matters: First bispecific + CD38 combo to show superior PFS and OS in Phase III in RRMM Potential new standard of care as early as second-line Demonstrates deep responses, high MRD-negativity, and durable outcomes First-line Strategies in BRAF V600E-Mutant mCRC: Real-World Evidence Signals Treatment Priorities In a real-world retrospective cohort of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), frontline chemotherapy plus anti-VEGF therapy was associated with the longest survival outcomes, while BRAF-targeted strategies showed promising response rates, emphasizing the need for tailored therapy and prospective validation
Write the concentration (e.g., "10mg/mL"), the date, and optionally the mcg-per-unit value on the vial with a permanent marker
The good news is that there are multiple evidence-based treatment options, and many patients improve with the right clinician-guided plan
Collection: Our products BPC-157 Ultra for Injury Recovery Regular price $102.00 USDRegular priceUnit price / per Sale price $102.00 USD Sale Wolverine Stack Regular price $150.00 USDRegular priceUnit price / per $177.00 USD Sale price $150.00 USDSale BPC-157 Ultra Regular price $102.00 USDRegular priceUnit price / per Sale price $102.00 USD BoneFix Ultra Regular price $34.00 USDRegular priceUnit price / per Sale price $34.00 USD BoneFix Ultra and BPC-157 Ultra Bundle Regular price $116.00 USDRegular priceUnit price / per $136.00 USD Sale price $116.00 USDSale
Her focus is on accuracy and fidelity to current published research, with all content presented for laboratory research use only